Company intelligence / Profile preview
InnoCure Therapeutics
Seongnam-si, Gyeonggi-do, Korea, Republic ofinnocurethera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Complete pre-clinical development result of cMET-targeted oral degrader ICTP-101 for NSCLC will be available in August 2025. IND for a global phase 1 study will be filed to US FDA by November 2025. ICTP-101 is being developed as monotherapy for NSCLC patients with cMET amplification and as combination therapy for NSCLC patients with resistance after MET-TKIs or EGFR-TKIs treatment.
- Therapeutic areas
- OncologyHematology
- Modalities
- Proteolysis-targeting chimeras (PROTAC)Molecular GlueDegrader Antibody Conjugates (DAC)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on InnoCure Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnoCure Therapeutics.